Cargando…

BC-PROM: validation of a patient-reported outcomes measure for patients with breast cancer

Key issues of treatment for patients with breast cancer such as patient satisfaction with treatments, compliance, and some side effects are essential for evaluating quality of life by patient-reported outcomes in clinical trials. The study aimed to develop and evaluate a specific patient-reported me...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiaojuan, Zhang, Chunsen, Zhang, Yanbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413279/
https://www.ncbi.nlm.nih.gov/pubmed/28445314
http://dx.doi.org/10.1097/MD.0000000000006781
_version_ 1783233157939593216
author Hu, Xiaojuan
Zhang, Chunsen
Zhang, Yanbo
author_facet Hu, Xiaojuan
Zhang, Chunsen
Zhang, Yanbo
author_sort Hu, Xiaojuan
collection PubMed
description Key issues of treatment for patients with breast cancer such as patient satisfaction with treatments, compliance, and some side effects are essential for evaluating quality of life by patient-reported outcomes in clinical trials. The study aimed to develop and evaluate a specific patient-reported measure which included physical, psychological, social, and therapeutic domain for assessing the survival of patients with breast cancer. The pool of items was drafted after a theoretical revision and cognitive interviews with women with breast cancer. The draft scale was formed after the adjustment of the items and dimensions, and the selected items were submitted to expert's judgments. Five statistical methods were used to select these items by 2 validation samples. The final scale was administered to a sample of 417 patients from 8 hospitals and 135 controls for reliability, validity, and responsive analyses. The final BC-PROM consisted of 52 items, 13 subdomains, and 4 domains, being developed after preexamination and formal examination. Cronbach alpha coefficient was 0.902 and 0.712 for the full scale and therapeutic domain. The structural validity results showed that the multidimensional measurement of the scale fulfilled expectations. Differences in the BC-PROM mean scores were significant between cancer patients and healthy participants in 13 subdomains (P < .05), indicating good responsiveness. Among the sample survey of patients, the scale copy acceptance rate was 98.2%, completion rate 94.6%, and average filling time 10 minutes. The new and reliable BC-PROM was developed in patients with breast cancer and applied to clinical treatment evaluation and clinical trials for such patients.
format Online
Article
Text
id pubmed-5413279
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-54132792017-05-05 BC-PROM: validation of a patient-reported outcomes measure for patients with breast cancer Hu, Xiaojuan Zhang, Chunsen Zhang, Yanbo Medicine (Baltimore) 6600 Key issues of treatment for patients with breast cancer such as patient satisfaction with treatments, compliance, and some side effects are essential for evaluating quality of life by patient-reported outcomes in clinical trials. The study aimed to develop and evaluate a specific patient-reported measure which included physical, psychological, social, and therapeutic domain for assessing the survival of patients with breast cancer. The pool of items was drafted after a theoretical revision and cognitive interviews with women with breast cancer. The draft scale was formed after the adjustment of the items and dimensions, and the selected items were submitted to expert's judgments. Five statistical methods were used to select these items by 2 validation samples. The final scale was administered to a sample of 417 patients from 8 hospitals and 135 controls for reliability, validity, and responsive analyses. The final BC-PROM consisted of 52 items, 13 subdomains, and 4 domains, being developed after preexamination and formal examination. Cronbach alpha coefficient was 0.902 and 0.712 for the full scale and therapeutic domain. The structural validity results showed that the multidimensional measurement of the scale fulfilled expectations. Differences in the BC-PROM mean scores were significant between cancer patients and healthy participants in 13 subdomains (P < .05), indicating good responsiveness. Among the sample survey of patients, the scale copy acceptance rate was 98.2%, completion rate 94.6%, and average filling time 10 minutes. The new and reliable BC-PROM was developed in patients with breast cancer and applied to clinical treatment evaluation and clinical trials for such patients. Wolters Kluwer Health 2017-04-28 /pmc/articles/PMC5413279/ /pubmed/28445314 http://dx.doi.org/10.1097/MD.0000000000006781 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 6600
Hu, Xiaojuan
Zhang, Chunsen
Zhang, Yanbo
BC-PROM: validation of a patient-reported outcomes measure for patients with breast cancer
title BC-PROM: validation of a patient-reported outcomes measure for patients with breast cancer
title_full BC-PROM: validation of a patient-reported outcomes measure for patients with breast cancer
title_fullStr BC-PROM: validation of a patient-reported outcomes measure for patients with breast cancer
title_full_unstemmed BC-PROM: validation of a patient-reported outcomes measure for patients with breast cancer
title_short BC-PROM: validation of a patient-reported outcomes measure for patients with breast cancer
title_sort bc-prom: validation of a patient-reported outcomes measure for patients with breast cancer
topic 6600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413279/
https://www.ncbi.nlm.nih.gov/pubmed/28445314
http://dx.doi.org/10.1097/MD.0000000000006781
work_keys_str_mv AT huxiaojuan bcpromvalidationofapatientreportedoutcomesmeasureforpatientswithbreastcancer
AT zhangchunsen bcpromvalidationofapatientreportedoutcomesmeasureforpatientswithbreastcancer
AT zhangyanbo bcpromvalidationofapatientreportedoutcomesmeasureforpatientswithbreastcancer